Q-omics provides the consensus-scored HSPD1P16 profile across patient tissues and cancer cell-line models. HSPD1P16 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, HSPD1P16 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, HSPD1P16 RNA expression shows 10,822 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight CHOL, BRCA, and CCRCC as cancer lineages where HSPD1P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPD1P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPD1P16 survival associations across molecular data types. HSPD1P16 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPD1P16 RNA expression–survival associations across cancer types. High HSPD1P16 expression shows unfavorable associations in CHOL, UCEC, BRCA, LUSC and ESCA, but favorable associations in KIRC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for HSPD1P16 RNA expression.
This table summarizes HSPD1P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSPD1P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPD1P16 shows lower tumor expression in BRCA, KICH, LUSC and THCA and higher tumor expression in COAD and LIHC. The BRCA box plot shows higher HSPD1P16 RNA expression in normal versus tumor tissue (log2 FC = −0.243, t-test p < 0.001).
This table shows molecular features associated with HSPD1P16 in patient tissues and cancer cell lines. In patient samples, HSPD1P16 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
